This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Immutep said a collaboration with GSK remains in place and GSK2831781 continues to be under exclusive license with GSK. The company’s hopes for the drug lie in other autoimmune diseases – it has already been tested in a phase 1 psoriasis trial showing preliminary signs of efficacy.
Merimepodib is the subsidiary’s primary asset, and the biotech now says it is to offers to acquire or license the drug. The post BioSig abandons COVID-19 drugtrial on safety concerns appeared first on. BioSig has previously said it was considering a spin-out of ViralClear. Image credit: Rocky Mountain Labs/NIH.
It is the world’s first and only licensed malaria vaccine and also the first licensed for use against a human parasitic disease of any kind. Children have been the focus of malaria vaccine and drugtrials because over 90 percent of deaths attributable to malaria are in African children under the age of five.
LQTT has a portfolio of in-licensed compounds from Sanofi that prohibit serum/glucocorticoid-regulated kinase 1, or SGK1. AbbVie reported the success of two phase 3 trials of its drugtrial in October and filed for FDA approval in February.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content